We have known about Newcase.ai since May. The product combines medical records, testimony and other case materials, builds chronologies, identifies inconsistencies and supports the analysis of expert witnesses. Its scope is broader than that of AR3S, however, covering the entire litigation intelligence layer rather than focusing exclusively on the substantive assessment of a specific expert report.
Today, during another round of competitive research, I happen to come across two solutions that are even closer to parts of what we are trying to build: V7 Go and ArrowLex.
V7 Go explicitly promotes expert report analysis, methodology assessment, the identification of weaknesses and inconsistencies, report comparison, and the mapping of conclusions to source material. Functionally, this is already very close to some of the problems we are trying to solve. V7 remains a broad platform for automating the analysis of many different types of documents — from medical reports to technical, engineering and financial materials — rather than a product focused exclusively on medical expert reports used in litigation. We will nevertheless need to keep a very close eye on them.
ArrowLex is a platform designed for lawyers working with expert witnesses. It supports the analysis of expert reports, the preparation of questions and examination plans, the simulation of expert responses, and the comparison of testimony with case documents. It therefore operates within a very similar legal workflow, but focuses primarily on examination preparation and expert litigation more broadly.
My first reaction is frustration with myself. We have already sent an earlier version of the pitch deck to our first potential investors without including these companies. It looks a little as though we were unable to identify our own competition. The competition slide needs to be rebuilt immediately.
Worse still, these companies did not suddenly appear today. V7 has been operating for years, and it did not start analysing expert reports yesterday. ArrowLex does not look like a hastily assembled experiment either. The competition has not suddenly grown up in front of us — we are simply only now noticing that others have been approaching a similar problem from different directions for some time.
On the other hand, discovering products like these is also good news in a way. It shows that the need for deeper analysis of expert reports does not exist solely in my head. Perhaps we really are trying to solve a genuine problem, rather than create a market that nobody except us needs.
I still cannot find a product identical to AR3S — one combining medical specialisation with the systematic verification of the reasoning in a specific expert report and the identification of substantive grounds on which it can be challenged. We can no longer comfort ourselves, however, with the idea that we are operating in a completely empty category.
It is difficult not to feel a twinge of anxiety. We are still building the MVP, while on the other side there are companies with finished products, established teams, funding and a head start of several years. Being first will therefore not be enough — especially since we probably are not. We need to build a solution that is clearly better within our narrow use case: deeper, more reliable and genuinely useful to a lawyer confronting a medical expert report.
And we need to do it as quickly as possible.